Preventing clinically evident coronary heart disease in the postmenopausal woman

Menopause : the Journal of the North American Menopause Society
Francine K Welty

Abstract

This review summarizes data on the prevalent coronary heart disease risk factors of postmenopausal women and the pharmacologic and nonpharmacologic therapies available for preventing or treating them. Medline searches from 1966 on were used to identify manuscripts for coronary heart disease risk factor information, lipid levels as predictors of cardiovascular disease in women, non-pharmacologic therapies, side effects of statins, and lipid-lowering trials that included women and had myocardial infarction or coronary heart disease death as endpoints. Dyslipidemias that occur with menopause are particularly atherogenic and tend to cluster with other metabolic and nonmetabolic risk factors. Estrogen therapy, with or without progestogen, can no longer be recommended for primary or secondary prevention of cardiovascular disease in postmenopausal women. Statins have been effective in reducing cardiovascular-related morbidity and mortality and should be first-line therapy for lipid-lowering. A considerable number of women look to obstetricians-gynecologists for primary care. For postmenopausal women especially, primary care must include management of risk factors for coronary heart disease. Estrogen or estrogen plus progestin should b...Continue Reading

References

Jan 25, 1990·The New England Journal of Medicine·L RosenbergS Shapiro
Mar 29, 1990·The New England Journal of Medicine·J E MansonC H Hennekens
Sep 7, 1989·The New England Journal of Medicine·K A MatthewsR R Wing
May 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·R D AbbottW P Castelli
Jul 1, 1988·The Journal of Clinical Endocrinology and Metabolism·H CamposE J Schaefer
Nov 19, 1987·The New England Journal of Medicine·W C WillettC H Hennekens
Jun 29, 1995·The New England Journal of Medicine·J W Rich-EdwardsJ E Buring
Oct 1, 1993·Circulation·E D EakerM Winston
Jan 4, 1993·Atherosclerosis·J C StevensonI F Godsland
Jun 16, 1993·JAMA : the Journal of the American Medical Association·C L JohnsonK Lippel
May 22, 1996·JAMA : the Journal of the American Medical Association·W B Kannel
Aug 26, 1998·The Medical Clinics of North America·A J Garber
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·P W Wilson, B F Culleton
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
May 21, 1999·Archives of Internal Medicine·P W WilsonR B D'Agostino
Dec 28, 1999·JAMA : the Journal of the American Medical Association·J C LaRosaS Vupputuri
Aug 24, 2000·The New England Journal of Medicine·D M HerringtonD Waters
Mar 17, 2001·Archives of Internal Medicine·F K Welty
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 7, 2001·The New England Journal of Medicine·J E Manson, K A Martin
Oct 30, 2001·The New England Journal of Medicine·C M ViscoliR I Horwitz
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Jun 27, 2002·The American Journal of Cardiology·Robert H Knopp
Jul 2, 2002·JAMA : the Journal of the American Medical Association·Deborah GradyUNKNOWN HERS Research Group
Jul 11, 2002·The American Journal of Cardiology·Howard N HodisRoger Lobo
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Jul 16, 2002·JAMA : the Journal of the American Medical Association·Suzanne W Fletcher, Graham A Colditz

❮ Previous
Next ❯

Citations

May 9, 2008·Journal of Human Hypertension·A J HogarthD A S G Mary
Jan 15, 2005·Journal of Women's Health·Genovefa D KolovouDennis V Cokkinos
Sep 24, 2011·Journal of Hypertension·Andrew J HogarthJohn P Greenwood
May 13, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Terry A Jacobson
Jul 16, 2005·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Manuel Neves-e-Castro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Lancet
R H EckelPaul Z Zimmet
Archives of Internal Medicine
P W WilsonR B D'Agostino
The Medical Clinics of North America
A J Garber
© 2022 Meta ULC. All rights reserved